The Library
Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients : a randomized clinical trial
Tools
Sabico, Shaun, Al-Mashharawi, Ayah, Al-Daghri, Nasser M., Yakout, Sobhy, Alnaami, Abdullah M., Alokail, Majed S. and McTernan, Philip G. (2017) Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients : a randomized clinical trial. Journal of translational medicine, 15 (1). p. 249. doi:10.1186/s12967-017-1354-x ISSN 1479-5876.
|
PDF
WRAP-effects-multi-strain-probiotic-endotoxin-Sabico-2017.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1115Kb) | Preview |
Official URL: http://dx.doi.org/10.1186/s12967-017-1354-x
Abstract
The present randomized clinical trial characterized the beneficial effects of a multi-strain probiotics supplementation on improving circulating endotoxin levels (primary endpoint) and other cardiometabolic biomarkers (secondary endpoint) in patients with T2DM.A total of 78 adult Saudi T2DM patients (naïve and without co-morbidities) participated in this clinical trial and were randomized to receive twice daily placebo or probiotics [(2.5 × 109 cfu/g) containing the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58 (Ecologic®Barrier)] in a double-blind manner for 12 weeks. Anthropometrics and cardiometabolic profiles were obtained at baseline and after 12/13 weeks of treatment.After 12/13 weeks of intervention and using intention-to-treat analysis, no difference was noted in endotoxin levels between groups [Placebo - 9.5% vs. Probiotics - 52.2%; (CI - 0.05 to 0.36; p = 0.15)]. Compared with the placebo group however, participants in the probiotics groups had a significant but modest improvement in WHR [Placebo 0.0% vs. Probiotics 1.11%; (CI - 0.12 to - 0.01; p = 0.02)] as well as a clinically significant improvement in HOMA-IR [Placebo - 12.2% vs. Probiotics - 60.4%; (CI - 0.34 to - 0.01; p = 0.04)].Using a multi-strain probiotic supplement daily for 12/13 weeks significantly improved HOMA-IR and modestly reduced abdominal adiposity among medication naïve T2DM patients.ClinicalTrials.gov Identifier: NCT01765517.
Item Type: | Journal Article | ||||||
---|---|---|---|---|---|---|---|
Subjects: | Q Science > QP Physiology R Medicine > RC Internal medicine |
||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||
SWORD Depositor: | Library Publications Router | ||||||
Library of Congress Subject Headings (LCSH): | Non-insulin-dependent diabetes -- Treatment, Endotoxins, Probiotics, Clinical trials | ||||||
Journal or Publication Title: | Journal of translational medicine | ||||||
Publisher: | BMC | ||||||
ISSN: | 1479-5876 | ||||||
Official Date: | 11 December 2017 | ||||||
Dates: |
|
||||||
Volume: | 15 | ||||||
Number: | 1 | ||||||
Page Range: | p. 249 | ||||||
DOI: | 10.1186/s12967-017-1354-x | ||||||
Status: | Peer Reviewed | ||||||
Publication Status: | Published | ||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||
Date of first compliant deposit: | 2 October 2018 | ||||||
Date of first compliant Open Access: | 2 October 2018 | ||||||
RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year